Jiangsu Vcare Approved to Establish "Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center"
Published Time:
2024-11-01 17:51
Source:
Recently, the Nanjing Municipal Science and Technology Bureau announced the acceptance results of 2024 provincial-level engineering research centers and academician workstations. The"Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center", established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), successfully passed project acceptance.
Provincial Engineering Research Centers are key components of Jiangsu's innovation system and vital forces driving high-quality industrial development. Their mission is to promote technological innovation in Jiangsu by strengthening engineering R&D platforms, conducting R&D and technical services, developing common/key technologies, and providing mature technical processes, equipment, and products to facilitate achievement transformation and technological radiation.
During its establishment, the Center built a comprehensive integrated drug R&D platform covering drug discovery, synthesis, analysis, formulation, pharmacological screening, and clinical research. Leveraging this platform, it achieved notable outcomes including Vicagrel, VC004, and VC005—innovative drugs oriented to meeting clinical needs through differentiated solutions, now entering confirmatory clinical stages.
The Center has also cultivated professionals in drug design and clinical development, forming a high-caliber R&D team that enhances the company’s innovation and competitiveness. It will continue deepening R&D efforts to advance China’s pharmaceutical innovation.
Related News
20
2023
/
01
I. Corporate Development and Infrastructure ① Wholly-owned subsidiary Nanjing Vcare successfully acquired Hubei Tianshu Pharmaceutical Co., Ltd. ② CDMO Business Technology Center completed and operational. ③ Established new technology platform laboratories. ④ Built a new Innovative Drug Synthesis Technology Center.
View Details
27
2022
/
12
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed a Series B financing round exceeding CNY 200 million,which were led by Changjiang Venture Capital ,with participation from Hongcheng Capital and Hangzhou Huadian Investment, and continued support from Yangtze River Industry Group and SDIC Capital. The raised funds will be used to accelerate the clinical development of the company's core innovative drug products and the construction of its CDMO industrial base.
View Details
19
2022
/
05
Recently, Vicagrel capsules, a Class 1 novel antiplatelet agent developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received Clinical Trial Approval from the NMPA for the target indication of minor ischemic stroke (MIS) or transient ischemic attack (TIA). The related Phase II clinical trial is set to begin shortly.
View Details
06
2022
/
05
Jiangsu Vcare Closes Series A2 Financing
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series A2 financing round. This marks the successful closing of the company’s Series A financing, bringing the total Series A funding to nearly $60 million. This round was led by existing investor SDIC Capital, with co-investment from Yangtze River Industry Group. The proceeds will primarily support the R&D of innovative drug candidates as well as the construction of R&D and production bases for its CDMO business.
View Details
22
2021
/
11
On November 19, 2021, the first clinical trial participant was dosed with VC005 tablets, a highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare). The dosing was completed at the Phase I Clinical Research Center of the First Hospital of Jilin University, and the participant has now successfully completed the safety observation period.
View Details
18
2021
/
08
Initiation Meeting of FDA-FE Clinical Study of Vicagrel Capsules
On August 18, the kick-off meeting of the FDA-FE clinical study of Vicagrel Capsules, a Class I new drug of Jiangsu Vcare Pharmatech Co., Ltd. (Jaingsu Vcare), was held at the Phase I Clinical Research Center of the First Hospital of Jilin University. This marks the official launch of the FDA clinical study of Vicagrel in the United States and the supporting Phase III clinical study in China.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn